ABSTRACT
Perrault syndrome is a rare autosomal recessive disorder characterized by sensorineural hearing loss (SNHL) in both sexes and primary ovarian insufficiency in 46, XX karyotype females. Biallelic variants in five genes are reported to be causative: HSD17B4, HARS2, LARS2, CLPP and C10orf2. Here we present eight families affected by Perrault syndrome. In five families we identified novel or previously reported variants in HSD17B4, LARS2, CLPP and C10orf2. The proband from each family was whole exome sequenced and variants confirmed by Sanger sequencing. A female was compound heterozygous for a known, p.(Gly16Ser) and novel, p.(Val82Phe) variant in D-bifunctional protein (HSD17B4). A family was homozygous for mitochondrial leucyl aminocyl tRNA synthetase (mtLeuRS) (LARS2) p.(Thr522Asn), previously associated with Perrault syndrome. A further family was compound heterozygous for mtLeuRS, p.(Thr522Asn) and a novel variant, p.(Met117Ile). Affected individuals with LARS2 variants had low frequency SNHL, a feature previously described in Perrault syndrome. A female with significant neurological disability was compound heterozygous for p.(Arg323Gln) and p.(Asn399Ser) variants in Twinkle (C10orf2). A male was homozygous for a novel variant in CLPP, p.(Cys144Arg). In three families there were no putative pathogenic variants in these genes confirming additional disease-causing genes remain unidentified. We have expanded the spectrum of disease-causing variants associated with Perrault syndrome.
Subject(s)
Amino Acyl-tRNA Synthetases/genetics , DNA Helicases/genetics , Endopeptidase Clp/genetics , Gonadal Dysgenesis, 46,XX/genetics , Hearing Loss, Sensorineural/genetics , Mitochondrial Proteins/genetics , Peroxisomal Multifunctional Protein-2/genetics , Exome/genetics , Female , Genotype , Gonadal Dysgenesis, 46,XX/pathology , Hearing Loss, Sensorineural/pathology , Homozygote , Humans , Male , Mutation , Pedigree , Phenotype , Primary Ovarian Insufficiency/genetics , Primary Ovarian Insufficiency/physiopathologyABSTRACT
Lissencephaly is a phenotypically and genetically heterogeneous group of cortical brain malformations due to abnormal neuronal migration. The identification of many causative genes has increased the understanding of normal brain development. A consanguineous family was ascertained with three siblings affected by a severe prenatal neurodevelopmental disorder characterised by fronto-parietal pachygyria, agenesis of the corpus callosum and progressive severe microcephaly. Autozygosity mapping and exome sequencing identified a homozygous novel single base pair deletion, c.1197delT in DMRTA2, predicted to result in a frameshift variant p.(Pro400Leufs*33). DMRTA2 encodes doublesex and mab-3-related transcription factor a2, a transcription factor key to the development of the dorsal telencephalon. Data from murine and zebrafish knockout models are consistent with the variant of DMTRA2 (DMRT5) as responsible for the cortical brain phenotype. Our study suggests that loss of function of DMRTA2 leads to a novel disorder of cortical development.
Subject(s)
Cerebral Cortex/abnormalities , Genetic Predisposition to Disease/genetics , Lissencephaly/genetics , Mutation , Animals , Base Sequence , Consanguinity , Disease Models, Animal , Exome/genetics , Family Health , Female , Humans , Male , Mice , Pedigree , Sequence Analysis, DNA/methods , Siblings , Transcription Factors , Xenopus/genetics , Zebrafish/geneticsABSTRACT
Cutaneous lesions described as chilblain lupus occur in the context of familial chilblain lupus or Aicardi-Goutières syndrome. To date, seven genes related to Aicardi-Goutières syndrome have been described. The most recently described encodes the cytosolic double-stranded RNA receptor IFIH1 (also known as MDA5), a key component of the antiviral type I interferon-mediated innate immune response. Enhanced type I interferon signalling secondary to gain-of-function mutations in IFIH1 can result in a range of neuroinflammatory phenotypes including classical Aicardi-Goutières syndrome. It is of note that none of the patients with a neurological phenotype so far described with mutations in this gene was reported to demonstrate cutaneous involvement. We present a family segregating a heterozygous pathogenic mutation in IFIH1 showing dermatological involvement as a prominent feature, variably associated with neurological disturbance and premature tooth loss. All three affected individuals exhibited increased expression of interferon-stimulated genes in whole blood, and the mutant protein resulted in enhanced interferon signalling in vitro, both in the basal state and following ligand stimulation. Our results further extend the phenotypic spectrum associated with mutations in IFIH1, indicating that the disease can be confined predominantly to the skin, while also highlighting phenotypic overlap with both Aicardi-Goutières syndrome and Singleton-Merten syndrome.
Subject(s)
Aortic Diseases/genetics , Autoimmune Diseases of the Nervous System/genetics , DEAD-box RNA Helicases/genetics , Dental Enamel Hypoplasia/genetics , Metacarpus/abnormalities , Muscular Diseases/genetics , Mutation/genetics , Nervous System Malformations/genetics , Odontodysplasia/genetics , Osteoporosis/genetics , Skin Diseases, Genetic/genetics , Vascular Calcification/genetics , Adult , Aortic Diseases/pathology , Autoimmune Diseases of the Nervous System/pathology , Chilblains/genetics , Child, Preschool , Dental Enamel Hypoplasia/pathology , Heterozygote , Humans , Infant , Interferon-Induced Helicase, IFIH1 , Lupus Erythematosus, Cutaneous/genetics , Male , Metacarpus/pathology , Muscular Diseases/pathology , Nervous System Diseases/genetics , Nervous System Malformations/pathology , Odontodysplasia/pathology , Osteoporosis/pathology , Phenotype , Skin Diseases, Genetic/pathology , Tooth Loss/genetics , Vascular Calcification/pathologySubject(s)
Adrenergic beta-Antagonists/therapeutic use , Drug Monitoring/methods , Heart Failure/drug therapy , Lung Diseases, Obstructive/drug therapy , Specialization , Adrenergic beta-Antagonists/blood , Aged , Aged, 80 and over , Cohort Studies , Drug Monitoring/standards , Female , Heart Failure/blood , Heart Failure/diagnosis , Humans , Lung Diseases, Obstructive/blood , Lung Diseases, Obstructive/diagnosis , Male , Middle Aged , Specialization/standardsABSTRACT
Despite widespread statin therapy, 91% of cardiac transplant patients have hyperlipidemia within 5 years from cardiac transplantation. The implications of this are profound, particularly given that coronary allograft vasculopathy is a leading cause of death. Unfortunately the solution is not easy, with problems of toleration at higher statin doses and a lack of good quality evidence for second line agents. We review the literature and discuss some of the key issues transplant physicians are faced with when considering alternatives to statin therapy.
Subject(s)
Heart Transplantation/adverse effects , Hyperlipidemias/therapy , Azetidines/therapeutic use , Bezafibrate/therapeutic use , Diet , Exercise , Ezetimibe , Fish Oils/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Niacin/therapeutic useABSTRACT
INTRODUCTION: Conventional imaging (CI) is known to have limitations with respect to staging of patients with primary or relapsed prostate cancer. Positron emission tomography/computed tomography (PET/CT) with (18)F-flurodeoxyglucose (FDG) is also often suboptimal because of low tracer avidity, but (18)F-fluorocholine (FCH) appears to be a promising alternative molecular imaging probe. We report a prospective pilot study of PET/CT comparing both tracers for staging and restaging of patients with prostate cancer. METHODS: Sixteen prostate cancer patients were evaluated (7 for staging and 9 for restaging). All patients also underwent CI, comprising at least an abdominopelvic CT and a bone scan. All imaging results and other relevant data were extracted from the imaging reports and medical charts. RESULTS: Based on all imaging-detected disease sites, both FCH-PET/CT and FDG-PET/CT (79%) were more sensitive than CI (14%), with the highest number of sites of nodal and distant disease on FCH PET/CT. FCH-PET/CT alone would have provided sufficient clinical information to form an appropriate management plan in 88% of cases, as compared with 56% for CI. CONCLUSION: FCH-PET/CT has the potential to impact on the management of patients with prostate cancer significantly more often than CI.
Subject(s)
Choline/analogs & derivatives , Fluorodeoxyglucose F18 , Positron-Emission Tomography/methods , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/pathology , Tomography, X-Ray Computed/methods , Aged , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Staging , Pilot Projects , Prospective Studies , Prostate/diagnostic imaging , Prostate/pathology , Radiographic Image Enhancement/methods , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
The aim of this study is to prospectively evaluate and model surrogate explanatory variables (SEVs) of target coverage and rectal dose pertaining to soft tissue anatomy visualised on cone beam computed tomography (CBCT) for incorporation into post-prostatectomy treatment coverage verification protocols. Twenty post-prostatectomy patients treated with conformal prostate bed radiotherapy (64-74 Gy) underwent CBCT daily at fractions 1 to 5, and then weekly. Treatment coverage was defined on each CBCT using 'PTV95', percentage of the CBCT PTV covered by original treatment fields, and 'RECTD50', dose delivered to 50% of CBCT rectal volume by original treatment fields. Three candidate SEVs for treatment coverage were defined for each scan: anterior rectal wall movement, change in bladder length and bladder base movement. Both anterior rectal wall movement and increase in bladder length predicted for the decreased PTV95 (P < 0.001 for each). Anterior movement of the anterior rectal wall predicted for increased RECTD50 (P < 0.001). Predictive models for the PTV95 and RECTD50 that accept the significant SEVs as inputs were developed. We developed simple CBCT-acquired soft tissue anatomic surrogate measures that signal changes in target coverage and rectal dose during post-prostatectomy radiotherapy. Conventional bony anatomy patient position verification protocols were inadequate in accounting for soft tissue target and organ variation seen with CBCT.
Subject(s)
Cone-Beam Computed Tomography/methods , Decision Support Techniques , Outcome Assessment, Health Care/methods , Prostatectomy/methods , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/therapy , Humans , Male , Postoperative Care/methods , Prognosis , Radiotherapy, Adjuvant/statistics & numerical data , Treatment OutcomeABSTRACT
Radiation therapy aimed at curing prostate cancer forms a considerable workload in most contemporary radiation oncology departments. The wide range of currently available therapeutic strategies for this cancer and their increasing complexity further increases the impact these patients have within the treating unit. Grounded in basic anatomy, physiology and pathology, the rationale for the division of prostate cancers into different prognostic and therapeutic groups is discussed, and put into clinical context using the current research evidence base. Weaknesses in this evidence base are highlighted in relation to areas directly impacted on by the work of medical physics.
Subject(s)
Health Physics/methods , Prostatic Neoplasms/radiotherapy , Biomedical Engineering/methods , Biomedical Engineering/trends , Health Physics/trends , Humans , Male , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/pathology , Radiobiology/methods , Radiobiology/trendsABSTRACT
Following cardiac transplantation, many patients develop chronic deterioration of graft function, which may lead to a clinical syndrome similar to native chronic heart failure (CHF). This condition of chronic cardiac graft failure (CGF) may also share pathophysiological processes comparable with that of CHF. However, the unique environment following cardiac transplantation may also contribute with a variety of unique mechanisms, deserved of special attention. This review article discusses the complex pathophysiology of CGF after cardiac transplantation, an important yet neglected condition of transplant medicine.
Subject(s)
Graft Rejection/physiopathology , Heart Failure/surgery , Heart Transplantation , HumansABSTRACT
BACKGROUND: The innate immune system plays an important role in cardiac allograft rejection. BNP has frequently been reported to elevate during acute cardiac rejection, yet the explanation behind this phenomenon is unclear. We hypothesized that BNP might interact with the innate immune system in cardiac transplant recipients and devised a series of in vitro culture experiments to explore this phenomena. METHODS: PBMCs were isolated from whole blood of (total n = 40) cardiac transplant recipients. Short (24h, n = 20) and long term (72h, n = 20) co-cultures of innate cells in the presence or absence of BNP were performed. BNP was added at two specific concentrations and compared to placebo control. Innate cells were immunophenotyped using flow cytometry. RESULTS: BNP dose dependently reduced the total number of monocytes, B cells and NK cells. Furthermore, BNP co-culture impaired NK cell cytotoxicity and adhesion of non-classical monocytes (via down-regulation of CD11c). DISCUSSION: BNP has an additional physiological role of moderating components of the innate immune system. Although speculative, this could be beneficial to cardiac transplant recipients as the innate immune system is involved in allograft rejection. Further investigation is required to elucidate the mechanism behind how BNP affects immune cells and whether the same effects are consistent with the adaptive immune system.
Subject(s)
Heart Transplantation/immunology , Immunity, Innate/immunology , Leukocytes, Mononuclear/drug effects , Natriuretic Agents/pharmacology , Natriuretic Peptide, Brain/pharmacology , Cells, Cultured , Dose-Response Relationship, Drug , Flow Cytometry , Humans , Immunity, Innate/drug effects , Leukocytes, Mononuclear/immunology , Reference StandardsABSTRACT
3-hydroxy-3-methyglutaryl CoA reductase inhibitors (statins) are frequently used following organ transplantation and have well reported pleiotropic effects, including immunomodulation, which may be of benefit in preventing graft rejection. However, the immunomodulatory effects of statins on cell transformation and malignancy, combined with the immunologic processes and administration of immunosuppression are almost completely unknown. The administration of immunosuppression is well recognised as the main cause of cancer following transplantation, so the addition of an immunomodulatory agent should be associated with an increased incidence of cancer, as immune surveillance and response may be suppressed, allowing cellular transformation and proliferation combined with lack of recognition to occur. This hypothetical review attempts to delineate the mode of action of statins in terms of pro/anti-carcinogenic mechanisms, while considering graft rejection and the presence of immunosuppression.
Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Neoplasms/etiology , Neoplasms/immunology , Organ Transplantation/methods , Animals , Cell Adhesion , Cell Proliferation , Chemotaxis , Graft Rejection , Humans , Immune System , Immunosuppressive Agents/pharmacology , Killer Cells, Natural/metabolism , Mevalonic Acid/metabolism , Models, Biological , Neoplasms/drug therapyABSTRACT
INTRODUCTION: Following lung transplantation, cytomegalovirus (CMV) has both direct and indirect adverse effects on the allograft. Natural killer cells mediate immune responses to CMV. This can be both dependent and independent of MHC class I expression. However, their role during CMV infection following lung transplantation is unknown. In this study, the immunophenotypic characteristics of NK cells were correlated with CMV infection following lung transplantation. METHODS: Seventy lung transplant recipients were included in the study. NK cells were characterised via flow cytometric analysis of CD3, CD16, CD56, CD107a, CD107b, and CD161. CMV infection was determined using an established quantitative PCR technique on peripheral blood. RESULTS: The number of peripheral blood NK cells with CD16, CD56 and CD161 phenotypes decreased in patients with CMV infection. However, there were no correlations between CMV infection and NK cell activation determined via LAMP expression. CONCLUSIONS: This study reports comparative differences in the peripheral blood NK cell repertoire in lung transplant recipients with CMV infection versus those without. However, NK cell activity did not alter with CMV infection, suggesting that CMV infection alone does not induce an NK cell response.
Subject(s)
Cytomegalovirus Infections/immunology , Cytomegalovirus , Killer Cells, Natural/immunology , Lung Transplantation/immunology , Lymphocyte Activation/immunology , Lymphocyte Subsets/immunology , Adult , Cell Count , Clonal Deletion/immunology , Cytomegalovirus Infections/blood , Cytotoxicity, Immunologic/immunology , Female , HLA Antigens/immunology , HLA Antigens/metabolism , Humans , Immunophenotyping , Killer Cells, Natural/virology , Lymphocyte Subsets/virology , Male , Middle Aged , Polymerase Chain ReactionABSTRACT
BACKGROUND: Monocytes mediate immune responses following solid organ transplantation via cytokine secretion and differentiation to macrophage/dendritic cell lineages. To date, the pleiotropic immunomodulatory effect of statins on human monocytes following human heart transplantation has yet to be elucidated. This study was designed to assess the effects of statin administration on the monocyte repertoire. METHODS: 108 patients were recruited into the study. Clinical data were collected from patients' notes. Peripheral blood immunophenotype was determined via flow cytometry (using CD11c, CD14, CD16, CD49d, CD64, CD80 and CD195). RESULTS: There were fewer circulating classical (p=0.0001) and non-classical (p=0.0013) monocytes in patients treated with a statin. CD64 expression was down-regulated (p=0.011 and p=0.049) whereas CD49d expression was up-regulated (p=0.004 and p=0.022) on classical and non-classical monocytes in this group. Patients receiving Atorvastatin had fewer circulating classical monocytes (p=0.001) compared to patients administered Pravastatin. Patients receiving Pravastatin had fewer circulating non-classical monocytes (p=0.029) compared to patients administered Atorvastatin. DISCUSSION: Statin administration alters the circulating monocyte repertoire following heart transplantation, including population size, FcgammaRI and VLA-4 adhesion molecule expression. Furthermore, different statin treatments are associated with a selective depletion of macrophage or DC (re)generating monocytes.
Subject(s)
Heart Transplantation/immunology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Integrin alpha4/metabolism , Monocytes/immunology , Receptors, IgG/metabolism , Adult , Aged , Atorvastatin , Cross-Sectional Studies , Down-Regulation , Female , Heptanoic Acids/pharmacology , Heptanoic Acids/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Integrin alpha4/immunology , Leukocyte Count , Male , Middle Aged , Monocytes/drug effects , Monocytes/metabolism , Pravastatin/pharmacology , Pravastatin/therapeutic use , Pyrroles/pharmacology , Pyrroles/therapeutic use , Receptors, IgG/immunology , Up-RegulationABSTRACT
Despite significant advances in the pharmacological treatment of heart failure, rates of mortality and morbidity from the condition remain a concern. The introduction of cardiac resynchronisation therapy (CRT) has been a welcome addition to the treatment strategy of patients who display ventricular dyssynchrony. Several control studies have shown significant benefits from this intervention in particular improved mortality and reduction in symptom burden. In this short review, we focus on several concepts of CRT and discuss the implications of surgical implantation of the left ventricular (LV) lead as compared to the standard transvenous approach.
Subject(s)
Cardiac Pacing, Artificial , Heart Block/etiology , Heart Block/therapy , Heart Failure/complications , Pacemaker, Artificial , Prosthesis Implantation/methods , Defibrillators, Implantable , Heart Failure/surgery , HumansSubject(s)
Adrenergic beta-Antagonists/therapeutic use , Heart Failure/drug therapy , Renal Insufficiency, Chronic/drug therapy , Adult , Aged , Aged, 80 and over , Anemia/drug therapy , Anemia/etiology , Creatinine/metabolism , Female , Humans , Male , Middle Aged , Renal Insufficiency, Chronic/physiopathology , Retrospective StudiesABSTRACT
BACKGROUND: 'Re-infection' with Helicobacter pylori after eradication has been estimated to occur in 0-14% of patients, although most so-called 're-infections' occur within the first year following 'eradication' and many may actually be due to recrudescence of a temporarily suppressed infection. AIM: To study the true re-infection rate, we have studied re-infection rates after eradication therapy by excluding the first year's data, minimizing the possible confounding effect of recrudescence. METHODS: All patients tested for H. pylori infection following eradication therapy between 1987 and 2004 were evaluated. Testing was carried out by urea breath test and gastric biopsy. Patients were included if they were found to be negative for H. pylori infection by testing at least 1 year following eradication and underwent at least one further test for H. pylori. RESULTS: 1162 patients met the inclusion criteria with median post-eradication follow-up of 3 years (1.5-14) including 4668 tests; 3319 years of follow-up were analysed. Thirteen cases of re-infection occurred (re-infection rate 0.4% per year). CONCLUSIONS: This large study of H. pylori re-infection avoided cases of recrudescence by excluding the first post-eradication year. True re-infection is probably less common than previously thought.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Gastrointestinal Diseases/prevention & control , Helicobacter Infections/diagnosis , Helicobacter pylori , Adult , Aged , Cohort Studies , Female , Follow-Up Studies , Gastrointestinal Diseases/microbiology , Helicobacter Infections/drug therapy , Humans , Male , Middle Aged , Prospective Studies , Recurrence , Risk FactorsABSTRACT
AIMS: The extent of exercise intolerance in patients with chronic heart failure (CHF) is dependent on and representative of the severity of heart failure. However, few primary care physicians have direct access to facilities for formal exercise testing. We have therefore explored whether information readily obtainable in the community can reliably predict the functional capacity of patients. METHODS AND RESULTS: Ninety-six subjects with a wide range of cardiac function (10 healthy controls and 86 CHF patients with NYHA classes I-IV, LVEF 36.9+/-15.2%) were recruited into the study and had resting plasma N-BNP and cardiopulmonary exercise testing to measure peak oxygen consumption (VO2). Significantly higher N-BNP levels were found in the CHF group (299.3 [704.8] fmol/ml, median [IQR]) compared with the healthy control group (7.2 [51.2] fmol/ml), p<0.0001. There were significant correlations between peak VO2 and N-BNP levels (R=0.64, P<0.001), peak VO2 and NYHA class (R=0.76, P=0.001), but no significant correlation was seen between peak VO2 and LVEF (R=0.0788, P=0.33). Multivariate analysis identified plasma N-BNP (P<0.0001) and NYHA class (P<0.0001) as significant independent predictors of peak VO2. Logistic modelling with NYHA class and log N-BNP to predict peak VO2<20 ml/kg/min showed that the area under the curve of receiver-operating-characteristic (ROC) curve was 0.906 (95% CI 0.844-0.968). A nomogram based on the data has been constructed to allow clinicians to estimate the likelihood of peak VO2 to be <20 ml/kg/min for given values of plasma N-BNP and NYHA class. CONCLUSIONS: By combining information from a simple objective blood test (N-BNP) and a simple scoring of functional status (NYHA), a clinician can deduce the aerobic exercise capacity and indirectly the extent of cardiac dysfunction of patients with CHF.